| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Adagene Inc. | muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98) | Solid tumors | Phase 2 | Ongoing | Intravenous infusion | Oncology |
| Adagene Inc. | ADG106-P2001 | Solid tumors | Phase 2 | Ongoing | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | ADP-A2M4CD8 - (SURPASS-3) | Ovarian Cancer | Phase 2 | Clinical Pause | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | ADP-A2M4CD8 - (SURPASS-2) | Esophageal and esophagogastric junction cancers | Phase 2 | Trial Completed | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | Afami-cel - (SPEARHEAD-2) | Head & neck cancer | Phase 2/3 | Trial Completed | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | ADP-A2M4CD8 - (SURPASS-2) | Esophageal and esophagogastric junction cancers | Phase 2 | Trial Completed | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | Lete-cel - (IGNYTE-ESO) | Sarcoma | BLA Filing | Data Released | Intravenous | Oncology |
| Adaptimmune Therapeutics plc | ADP-A2M4CD8 - (SURPASS-3) | Ovarian Cancer | Phase 2 | Clinical Pause | Intravenous | Oncology |